PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35228263-0	2022	Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers.	Nitrogen	60-61	interleukin 15	Homo sapiens	78-83	
35228263-1	2022	The oncotherapeutic promise of IL-15, a potent immunostimulant, is limited by a short serum t 1/2 The fusion protein N-803 is a chimeric IL-15 superagonist that has a >20-fold longer in vivo t 1/2 versus IL-15.	Nitrogen	117-118	interleukin 15	Homo sapiens	31-36	
35228263-1	2022	The oncotherapeutic promise of IL-15, a potent immunostimulant, is limited by a short serum t 1/2 The fusion protein N-803 is a chimeric IL-15 superagonist that has a >20-fold longer in vivo t 1/2 versus IL-15.	Nitrogen	117-118	interleukin 15	Homo sapiens	137-142	
35228263-1	2022	The oncotherapeutic promise of IL-15, a potent immunostimulant, is limited by a short serum t 1/2 The fusion protein N-803 is a chimeric IL-15 superagonist that has a >20-fold longer in vivo t 1/2 versus IL-15.	Nitrogen	117-118	interleukin 15	Homo sapiens	204-209	
26563299-0	2016	Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation.	Nitrogen	82-83	interleukin 15	Homo sapiens	32-37	
30713787-0	2019	The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex.	Nitrogen	27-28	interleukin 15	Homo sapiens	89-94	
26563299-7	2016	The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied.	Nitrogen	24-25	interleukin 15	Homo sapiens	18-23	
26563299-8	2016	Mass analysis of intact IL-15 confirmed its N-glycosylation and suggested that Asn79-glycosylation partially prevents Asn77-deamidation.	Nitrogen	44-45	interleukin 15	Homo sapiens	24-29